AXL and neoplasm: These findings underscored the bifunctionalcapabilities of 33 (BPR5K230) with excellentoral bioavailability (F = 54.6%), inhibiting bothMER and AXL while modulating the tumor microenvironment and highlightingits diverse applicability for further studies to advance its therapeuticpotential.